BrightGene Bio Medical Technology C Working Capital to Net Assets Ratio
BrightGene Bio Medical Technology C working capital to net assets ratio. BrightGene Bio Medical Technology C (688166) has a Working Capital to Net Assets ratio of 15.0% as of June 2025. Working capital of CN¥386.93 Million (current assets of CN¥1.54 Billion minus current liabilities of CN¥1.16 Billion) is measured against net assets of CN¥2.59 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of BrightGene Bio Medical Technology C (2016–2024)
Working capital to net assets ratio of BrightGene Bio Medical Technology C from 2016 to 2024. This chart shows how BrightGene Bio Medical Technology C's Working Capital to Net Assets ratio has evolved across 9 annual periods from 2016 to 2024. As of June 2025, the ratio stands at 15.0%, reflecting working capital of CN¥386.93 Million against net assets of CN¥2.59 Billion CNY. See 688166 defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
BrightGene Bio Medical Technology C Working Capital to Net Assets Ratio by Year (2016–2024)
BrightGene Bio Medical Technology C working capital to net assets ratio by year from 2016 to 2024. The table below presents the year-by-year Working Capital to Net Assets ratio for BrightGene Bio Medical Technology C from 2016 to 2024, covering 9 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see BrightGene Bio Medical Technology C total assets.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 24.1% | CN¥587.89 Million | CN¥2.44 Billion | CN¥1.64 Billion | CN¥1.05 Billion | ▼ -13.8 pp |
| 2023 | 38.0% | CN¥917.49 Million | CN¥2.42 Billion | CN¥1.84 Billion | CN¥922.25 Million | ▼ -12.3 pp |
| 2022 | 50.3% | CN¥1.13 Billion | CN¥2.24 Billion | CN¥1.94 Billion | CN¥811.52 Million | ▲ +26.7 pp |
| 2021 | 23.5% | CN¥409.94 Million | CN¥1.74 Billion | CN¥993.01 Million | CN¥583.07 Million | ▼ -22.2 pp |
| 2020 | 45.7% | CN¥654.65 Million | CN¥1.43 Billion | CN¥946.36 Million | CN¥291.71 Million | ▼ -26.9 pp |
| 2019 | 72.6% | CN¥953.83 Million | CN¥1.31 Billion | CN¥1.06 Billion | CN¥108.21 Million | ▲ +13.5 pp |
| 2018 | 59.2% | CN¥457.29 Million | CN¥772.85 Million | CN¥562.81 Million | CN¥105.52 Million | ▲ +9.6 pp |
| 2017 | 49.5% | CN¥220.87 Million | CN¥446.02 Million | CN¥299.77 Million | CN¥78.89 Million | ▲ +29.0 pp |
| 2016 | 20.5% | CN¥45.11 Million | CN¥220.15 Million | CN¥209.15 Million | CN¥164.05 Million | — |